Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Kintor to Start US Trial of Baldness Treatment

publication date: Jul 12, 2021

Suzhou's Kintor Pharma will start a US Phase II trial of its treatment for male pattern baldness. Pyrilutamide is a small molecule topical androgen receptor antagonist that inhibits both the androgen receptor and androgen in hair follicle sebaceous glands, thereby treating androgenetic alopecia and acne. The trial is Kintor's fifth US clinical study. Kintor's China Phase II trial of pyrilutamide is nearing its conclusion, with top-line data expected sometime in Q3 of this year. More details....

Stock Symbol: (HK:9939)

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.